Malak T T, Broomfield J A J, Palmer A J R, Hopewell S, Carr A, Brown C, Prieto-Alhambra D, Glyn-Jones S
Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Lane, Oxford OX3 7LD, UK.
Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Lane, Oxford OX3 7LD, UK
Bone Joint Res. 2016 Jun;5(6):206-14. doi: 10.1302/2046-3758.56.2000568.
High failure rates of metal-on-metal hip arthroplasty implants have highlighted the need for more careful introduction and monitoring of new implants and for the evaluation of the safety of medical devices. The National Joint Registry and other regulatory services are unable to detect failing implants at an early enough stage. We aimed to identify validated surrogate markers of long-term outcome in patients undergoing primary total hip arthroplasty (THA).
We conducted a systematic review of studies evaluating surrogate markers for predicting long-term outcome in primary THA. Long-term outcome was defined as revision rate of an implant at ten years according to National Institute of Health and Care Excellence guidelines. We conducted a search of Medline and Embase (OVID) databases. Separate search strategies were devised for the Cochrane database and Google Scholar. Each search was performed to include articles from the date of their inception to June 8, 2015.
Our search strategy identified 1082 studies of which 115 studies were included for full article review. Following review, 17 articles were found that investigated surrogate markers of long-term outcome. These included one systematic review, one randomised control trial (RCT), one case control study and 13 case series. Validated surrogate markers included Radiostereometric Analysis (RSA) and Einzel-Bild-Röntgen-Analyse (EBRA), each measuring implant migration and wear. We identified five RSA studies (one systematic review and four case series) and four EBRA studies (one RCT and three case series). Patient Reported Outcome Measures (PROMs) at six months have been investigated but have not been validated against long-term outcomes.
This systematic review identified two validated surrogate markers of long-term primary THA outcome: RSA and EBRA, each measuring implant migration and wear. We recommend the consideration of RSA in the pre-market testing of new implants. EBRA can be used to investigate acetabular wear but not femoral migration. Further studies are needed to validate the use of PROMs for post-market surveillance.Cite this article: T. T. Malak, J. A. J. Broomfield, A. J. R. Palmer, S. Hopewell, A. Carr, C. Brown, D. Prieto-Alhambra, S. Glyn-Jones. Surrogate markers of long-term outcome in primary total hip arthroplasty: A systematic review. Bone Joint Res 2016;5:206-214. DOI: 10.1302/2046-3758.56.2000568.
金属对金属髋关节置换植入物的高失败率凸显了更谨慎引入和监测新植入物以及评估医疗设备安全性的必要性。国家关节注册处和其他监管服务无法在足够早的阶段检测出有故障的植入物。我们旨在确定初次全髋关节置换术(THA)患者长期预后的有效替代指标。
我们对评估预测初次THA长期预后替代指标的研究进行了系统评价。根据英国国家卫生与临床优化研究所的指南,长期预后定义为植入物在十年时的翻修率。我们检索了Medline和Embase(OVID)数据库。为Cochrane数据库和谷歌学术设计了单独的检索策略。每次检索均纳入从创刊至2015年6月8日的文章。
我们的检索策略共识别出1082项研究,其中115项研究纳入全文综述。经过综述,发现有17篇文章研究了长期预后的替代指标。其中包括1篇系统评价、1篇随机对照试验(RCT)、1篇病例对照研究和13篇病例系列研究。已得到验证的替代指标包括放射立体测量分析(RSA)和 Einzel-Bild-Röntgen-Analyse(EBRA),二者均用于测量植入物的移位和磨损。我们识别出5项RSA研究(1篇系统评价和4篇病例系列研究)和4项EBRA研究(1篇RCT和3篇病例系列研究)。已对患者术后6个月的报告结局测量指标(PROMs)进行了研究,但尚未根据长期预后进行验证。
本系统评价确定了初次THA长期预后的两个已得到验证的替代指标:RSA和EBRA,二者均用于测量植入物的移位和磨损。我们建议在新植入物上市前测试中考虑使用RSA。EBRA可用于研究髋臼磨损,但不能用于研究股骨移位。需要进一步研究以验证PROMs在上市后监测中的应用。引用本文:T. T. Malak, J. A. J. Broomfield, A. J. R. Palmer, S. Hopewell, A. Carr, C. Brown, D. Prieto-Alhambra, S. Glyn-Jones。初次全髋关节置换术长期预后的替代指标:一项系统评价。《骨关节研究》2016;5:206 - 214。DOI:10.1302/2046 - 3758.56.2000568。